Hikma Pharmaceuticals Share Discussion Threads

[its the oxman] 13/11/2020 13:24

Chart looks poised for move up to 3000p

[robertball] 05/11/2020 14:50

Sector wide

[bartyb] 05/11/2020 14:48

Anyone know why the drop

[montyhedge] 05/11/2020 11:39

Saying that I'm going buy, lol.

[montyhedge] 05/11/2020 08:49

I must admit I don't like these companies who to me leech off other pharma companies, I hope GSK hang on to Adair for has long has possible. Why do they have to give into generic companies.

[robertball] 05/11/2020 08:33

I was looking for a drop today after the run up this week.3000 - 3200

[its the oxman] 05/11/2020 08:21

Looking for 3000p now

[its the oxman] 05/11/2020 08:20

Positive update, more upside to enjoy here.

[robertball] 26/10/2020 08:53

Trading stmt next week?

[robertball] 22/10/2020 19:13

Is it just me or is this a tightly coiled spring about to leap up?

[18bt] 16/10/2020 06:28

Tipped in the IC this morning.

[robertball] 08/10/2020 19:21

Moving a bit

[robertball] 23/9/2020 06:59

Indeed...I'm just trying to figure out price reaction...oh well...we trundle on

[dartboard1] 22/9/2020 19:34

Dunno Robertball... they gave guidance for both outcomes... I think that indicates it wasn't certain. FCF from Hikma is pretty good. Take a look at same from Teva and Hikma gives good solid cash flow, with reasonable growth

[robertball] 22/9/2020 18:57

But Hikma said otherwise...so that's what the problem is...expectation change..and shows management aren't fully in control of the situation....

[montyhedge] 22/9/2020 11:52

Still way overpriced.

[steeplejack] 22/9/2020 09:24

The price will recover.The FDA approval is later than hoped but in the bigger scheme of things that's hardly a serious setback and actually the company thought such an outcome was quite possible as indicated by its guidance.

[robertball] 22/9/2020 08:16

Groundhog Day here

[scepticalinvestor] 22/9/2020 07:55

Another insane drop

[steeplejack] 22/9/2020 06:57

We now expect Generics revenue to be in the range of $720 million to $760 million and core operating margin to be around 21% for the full year. Our guidance includes $20 million to $40 million from generic Advair Diskus(R) , which we continue to expect to launch in the second half of the year. If we do not launch generic Advair Diskus(R) in 2020, we would now expect the core operating margin for the Generics business to be between 17% and 19%.7 August 2020.Half Year Report.